Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Methylmalonic Acidemia (MMA) Market Size Forecast: How Large Could The Market Become By 2030?
The market for methylmalonic acidemia (mma) has experienced robust expansion lately and is projected to continue its upward trajectory, moving from $9.94 billion in 2025 to $10.52 billion in 2026, demonstrating a compound annual growth rate of 5.8%. Factors contributing to this growth during the past period include heightened awareness surrounding rare diseases, an increase in newborn screening initiatives, advancements in metabolic disorder research, the development of superior diagnostic tools, and the early adoption of genetic testing methodologies.
The methylmalonic acidemia (mma) market is poised for substantial expansion, projecting a valuation of $13.06 billion by 2030, underpinned by a compound annual growth rate (CAGR) of 5.6%. This anticipated rise during the forecast period is fueled by several key factors, including the burgeoning field of precision therapeutics, continuous progress in gene and enzyme replacement therapies, increased financial commitment to rare disease drug development, the growing adoption of telehealth for metabolic monitoring, and a heightened emphasis on tailored nutritional strategies. Prominent trends shaping this market in the coming years are expected to be the development of therapies grounded in precision medicine, the utilization of artificial intelligence to aid in diagnosis and patient monitoring, the integration of rare disease data through cloud-based platforms, the implementation of automated biomanufacturing processes for enzyme-based treatments, and the use of immersive technologies for medical training concerning metabolic disorders.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22057&type=smp
Methylmalonic Acidemia (MMA) Market Development Factors: Which Trends Are Supporting Demand?
The escalating prevalence of metabolic ailments and insufficient vitamin levels is anticipated to stimulate the expansion of the methylmalonic acidemia (MMA) market. Metabolic disorders encompass conditions affecting nutrient processing, energy generation, or cellular chemical regulation, while vitamin deficiencies arise from inadequate bodily vitamin stores for essential functions. Factors contributing to this rise include suboptimal dietary habits, sedentary lifestyles, and elevated stress, with contemporary diets often rich in processed items, sugars, and unhealthy fats, yet deficient in vital nutrients. Such deficiencies and metabolic disruptions, particularly a lack of vitamin B12, interfere with methylmalonyl-CoA metabolism, leading to a buildup of methylmalonic acid and worsening the condition of methylmalonic acidemia (MMA). For example, data from the National Institutes of Health in November 2024 indicated a rise in vitamin B12 deficiency from 4.6% to 5.2% between the third and fourth quarters of 2023, accounting for an additional 507 cases. Consequently, the growing occurrence of metabolic disorders and vitamin deficiencies serves as a primary impetus for the methylmalonic acidemia (MMA) market.
Methylmalonic Acidemia (MMA) Market Driver: The Increasing Neonatal And Pediatric Population Driving The Market Growth Due To Higher Incidence Of Methylmalonic Acidemia
A growing number of newborns and children is expected to fuel the expansion of the methylmalonic acidemia market. This demographic, encompassing infants up to 28 days old and individuals under 18 years, is increasing due to advancements in maternal and neonatal healthcare, which have enhanced survival rates and lowered infant mortality, especially in developed countries. The expanding young population consequently increases the need for early detection and treatment of metabolic disorders through more extensive newborn screening initiatives. For instance, the Australian Bureau of Statistics reported in October 2025 that 292,318 births were registered in Australia in 2024, a 1.9% increase or 5,320 more births than in 2023, comprising 150,299 male and 142,019 female infants. Therefore, the augmenting neonatal and pediatric population directly contributes to the growth of the methylmalonic acidemia market.
Methylmalonic Acidemia (MMA) Market Segment Analysis: What Are The Major Market Categories?
The methylmalonic acidemia (mma) market covered in this report is segmented –
1) By Treatment Type: Dietary Management And Supplementation, Enzyme Replacement Therapy, Gene Therapy, Transplantation
2) By Disorder Type: Isolated Methylmalonic Aciduria, Combined Methylmalonic Aciduria, Homocystinuria
3) By Patient Age Group: Infant, Pediatric, Adult
4) By Route of Administration: Oral, Intravenous
5) By End User: Hospitals, Specialty Clinics, Homecare, Other End Users
Subsegments:
1) By Dietary Management And Supplementation: Vitamin B12 Supplementation, L-Carnitine Supplementation, Low-Protein Medical Diets
2) By Enzyme Replacement Therapy: Recombinant Enzyme Therapies, Investigational Enzymes
3) By Gene Therapy: AAV-Based Gene Therapy, Other Viral Vector-Based Therapies
4) By Transplantation: Liver Transplantation, Combined Liver–Kidney Transplantation
Methylmalonic Acidemia (MMA) Market Transformation Trends: Which Innovations Are Driving Change?
Within the methylmalonic acidemia (MMA) market, leading entities are concentrating their efforts on pioneering novel therapeutic approaches, specifically exploring mRNA-based treatments. These advancements aim to enhance patient outcomes by directly addressing the genetic origins of MMA and bolstering enzyme activity, thereby mitigating the buildup of harmful substances in individuals afflicted with the condition. mRNA-based therapies function by utilizing messenger RNA to guide cellular machinery in synthesizing particular proteins crucial for disease prevention or treatment, including genetic ailments and infectious diseases. A notable development occurred in June 2024 when Moderna, Inc., a prominent US pharmaceutical and biotechnology firm, secured FDA approval for the inclusion of mRNA-3705 within the START pilot program, representing a pivotal moment in the progression of therapies for uncommon disorders. This investigational therapy, mRNA-3705, is specifically developed for MMA stemming from MUT deficiency, with the objective of reinstating the deficient enzyme through the application of mRNA technology. The therapeutic strategy incorporates Moderna’s proprietary lipid nanoparticle (LNP) delivery system, which is also employed in the mRNA-3927 initiative targeting propionic acidemia. Furthermore, the FDA has bestowed orphan drug, fast track, and rare pediatric disease designations upon mRNA-3705, thereby streamlining its development timeline and accelerating its clinical journey.
Methylmalonic Acidemia (MMA) Market Leading Companies Driving Competitive Growth
Major companies operating in the methylmalonic acidemia (mma) market are Alexion Pharmaceuticals Inc., PTC Therapeutics Inc., Asklepios BioPharmaceutical Inc AskBio, Selecta Biosciences Inc, BridgeBio Pharma Inc., VectivBio Holding AG, Recordati Rare Diseases Inc., Agios Pharmaceuticals Inc., LogicBio Therapeutics Inc., Moderna Inc., Wockhardt Limited, Supriya Lifescience Ltd., HemoShear Therapeutics LLC, Deccan Nutraceuticals Pvt Ltd, Genespire, Bluebird Bio Inc, Takeda Pharmaceutical Company Limited, Sanofi, Orphan Technologies Ltd, Ultragenyx Pharmaceutical Inc, HemoShear Therapeutics LLC
Access The Complete Methylmalonic Acidemia (MMA) Market Report:
https://www.thebusinessresearchcompany.com/report/methylmalonic-acidemia-mma-global-market-report
Methylmalonic Acidemia (MMA) Market Geographic Landscape: Which Region Dominates Industry Growth?
North Americawas the largest region in the methylmalonic acidemia (MMA) market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the methylmalonic acidemia (mma) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
